Spontaneous pneumothorax is an uncommon complication of COVID-19 viral pneumonia. The exact incidence and risk factors are still unknown. Herein we review the incidence and outcomes of pneumothorax in over 3000 patients admitted to our institution for suspected COVID-19 pneumonia.
Respiratory Research 21, Article number: 233 (2020)
Respiratory Research 21, Article number: 230 (2020)
Early life exposure in the uterus had a long-term effect on children’s health. As the prevalence of allergies is increasing with a remarkable sex difference, very few studies have traced back to their early origins. We sought to investigate if maternal behavioral exposure, herein sleep, physical activity, and screen time during pregnancy is associated with childhood respiratory allergies. The sex difference would be examined.
The webinars are one-hour monthly educational events offered monthly from September to June each year. They will be held at 16h00 (UTC+2) (10h00 EST- UTC-4) generally on Thursday of the 3rd or 4th week of the month). An expert will discuss an important topic related to asthma and co-morbid conditions.
Free registration for InterAsma members (Become a member now)
Registration for non-members: € 40 https://interasma.org/2020-2021-interasma-webinars-registration/
24 September 2020 Pr Louis-P. Boulet: Overview of GINA 2020
29 October 2020 Dr Daniel J Jackson: Update on COVID, asthma and related diseases
26 November 2020 Dr Lawrence DuBuske: Eosinophilic Asthma
17 December 2020 Pr Jean Bousquet: Treatment of rhinitis – the ARIA program
21 January 2021 Pr Paul O’Byrne: Management of mild asthma
25 February 2001 Pr G. Walter Canonica: Update on severe asthma – new developments
25 March 2021 Pr Pascal Chanez: Inhaled and oral corticosteroids in asthma
22 April 2021 Pr Jonathan Bernstein: Environmental and workplace influences on asthma
27 May 2021 Pr Fulvio Braido: Perception of severe asthma and its treatment by Clinicians
Future conferences:
Pr Ignacio Ansotegui Allergy and airways- evaluation and treatments
Pr Carlos Nunes Epidemiology of asthma: global prevalence and consequences
https://interasma.org/2020-2021-interasma-webinars-registration/
|
|
|
|
|
|
|
|
|
|
Allergy, Asthma & Clinical Immunology 16, Article number: 72 (2020)
Abstract
Background
Current guidelines do not recommend performing aeroallergen skin prick testing (SPT) in chronic spontaneous urticaria (CSU).
Objective
The objective of this review was to investigate the presence of aeroallergen sensitization and markers of T2 inflammation in subjects with CSU.
Abstract
Background
Substantial experimental studies suggest a role for helminthes infections in the pathogenesis of allergies, but epidemiologic data have been inconsistent. Unlike to asthma, the association between helminthes infection and allergic rhinitis (AR) has been poorly studied. Therefore, we sought to evaluate the association between exposure to Ascaris and Toxocara infections and AR.
Clinical and Translational Allergy 10, Article number: 33 (2020)
Abstract
 |
| Vienna challenge chamber |
Allergen exposure chambers (AECs) have been developed for controlled allergen challenges of allergic patients mimicking natural exposure. As such, these facilities have been utilized e.g., for proof of concept, dose finding or the demonstration of onset of action and treatment effect sizes of antiallergic medication. Moreover, clinical effects of and immunological mechanisms in allergen immunotherapy (AIT) have been investigated in AECs. In Europe AIT products have to fulfill regulatory requirements for obtaining market authorization through Phase I to III clinical trials. Multiple Phase II (dose-range-finding or proof-of-concept) trials on AIT products have been performed in AECs. However, they are not accepted by regulatory bodies for pivotal (Phase III) trials and a more thorough technical and clinical validation is requested. Recently, a Position Paper of the European Academy of Allergy and Clinical Immunology (EAACI) has outlined unmet needs in further development of AECs. The following review aims to address some of these needs on the basis of recently published data in the first part, whereas the second part overviews published examples of most relevant Phase II trials in AIT performed in AEC facilities.
